impact factor, citescore
logo
 

Letters to the Editor

 

Upadacitinib and ustekinumab combination treatment for a refractory case of spondyloarthritis and Crohn's disease


1, 2, 3, 4, 5

 

  1. Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy.
  2. Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy.
  3. Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy.
  4. Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy.
  5. Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Italy. stefano.gentileschi@unisi.it

CER17005
Letters to the Editor

Free to view
(click on article PDF icon to read the article)

PMID: 37812461 [PubMed]

Received: 20/07/2023
Accepted : 14/09/2023
In Press: 05/10/2023

Rheumatology Article